Management of allergic rhinitis – short review of literature 2014
Article Sidebar
Published:
Jun 30, 2014
Main Article Content
Abstract
None
Downloads
Download data is not yet available.
Article Details
How to Cite
Lipiec, A. (2014). Management of allergic rhinitis – short review of literature 2014. Alergoprofil, 10(2), 3-4. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/791
Issue
Section
Article
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Jutel M., Papadopoulos N.G., Gronlund H. et al.: Recommendations for the allergy management in the primary care. Allergy 2014; 69(6): 708-718.
2. Samoliński B., Arcimowicz M., Buczyłko K. i wsp.: (Polskie Standardy Leczenia Nieżytów Nosa – PoSLeNN) Alergologia Polska 2012; 1: 17-167.
3. Derendorf H., Meltzer E.O., Hermann R., Canonica G.W.: Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Drugs Today 2014; 50(1): 15-31.
4. Berger W.E., Shah S., Lieberman P. et al.: Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J. Allergy Clin. Immunol. Pract. 2014; 2(2): 179-185.
5. D’Addio D.A., Ruiz N.M., Mayer M.J. et al.: Deposition characteristics of a new allergic rhinitis nasal spray (MP29-02*) in an anatomical model of the human nasal cavity. Poster session on EAACI Congress, Kopehagen 7-11.06.2014.
6. Canonica G.W., Mösges R., Valovirta E. et al.: A new allergic rhinitis therapy (MP29-02*) provides ocular symptom relief days faster than current firstline monotherapies. Poster session on EAACI Congress, Kopehagen 7–11.06.2014.
7. Virchow C., Mösges R., Fenton J. et al.: A new allergic rhinitis therapy (MP29-02*) provides substantial and complete ocular symptom relief. Poster session on EAACI Congress, Kopehagen 7–11.06.2014.
8. Bachert C., Price D., Fokkens W. et al.: A new intranasal therapy MP29-02* is more effective than current firstline therapy regardless of season, symptom or severity. Poster session on EAACI Congress, Kopehagen 7–11.06.2014.
9. Klimek L., Virchow J.C., Wahn U. et al.: Real-world effectiveness of a new allergic rhinitis therapy (MP29-02*). Poster session on EAACI Congress, Kopehagen 7–11.06.2014.
2. Samoliński B., Arcimowicz M., Buczyłko K. i wsp.: (Polskie Standardy Leczenia Nieżytów Nosa – PoSLeNN) Alergologia Polska 2012; 1: 17-167.
3. Derendorf H., Meltzer E.O., Hermann R., Canonica G.W.: Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Drugs Today 2014; 50(1): 15-31.
4. Berger W.E., Shah S., Lieberman P. et al.: Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J. Allergy Clin. Immunol. Pract. 2014; 2(2): 179-185.
5. D’Addio D.A., Ruiz N.M., Mayer M.J. et al.: Deposition characteristics of a new allergic rhinitis nasal spray (MP29-02*) in an anatomical model of the human nasal cavity. Poster session on EAACI Congress, Kopehagen 7-11.06.2014.
6. Canonica G.W., Mösges R., Valovirta E. et al.: A new allergic rhinitis therapy (MP29-02*) provides ocular symptom relief days faster than current firstline monotherapies. Poster session on EAACI Congress, Kopehagen 7–11.06.2014.
7. Virchow C., Mösges R., Fenton J. et al.: A new allergic rhinitis therapy (MP29-02*) provides substantial and complete ocular symptom relief. Poster session on EAACI Congress, Kopehagen 7–11.06.2014.
8. Bachert C., Price D., Fokkens W. et al.: A new intranasal therapy MP29-02* is more effective than current firstline therapy regardless of season, symptom or severity. Poster session on EAACI Congress, Kopehagen 7–11.06.2014.
9. Klimek L., Virchow J.C., Wahn U. et al.: Real-world effectiveness of a new allergic rhinitis therapy (MP29-02*). Poster session on EAACI Congress, Kopehagen 7–11.06.2014.